Cheryl Guttman Krader, BS, Pharm

Survey respondents point to a perceived gap in treatments for uveitic macular edema, document interest in suprachoroidal drug delivery.

Recent literature review reveals dearth of data, highlights need for more research.

Confronting issues unique to aging may lead to better outcomes.

XIPERE, the first therapy utilizing the suprachoroidal space, demonstrates rapid efficacy, durable benefit, and favorable safety profile.

Organization looks to improve global eye care through ophthalmic education.

Ophthalmologists face challenges of drug delivery for retinal diseases.

Option detects treatment-naive nonexudative macular neovascularization in eyes with dry age-related macular degeneration.

FDA will be asked to consider ONS-5010 for treating wet AMD.

Why investigators are considering AMD to be a disease spectrum rather than a single disease.

Dual imaging may reduce costs, unnecessary referrals, telehealth study results show.

Dexamethasone implant is key to treating non-infectious posterior segment uveitis

Eyes with chronic disease responded to steroid treatment

Technology helps physicians understand normal and abnormal macular anatomy

Key is to recognize usual patterns for systemic and topical medications

Ophthalmologist provides patient counseling pearls for selected retinal dystrophies

Study highlights role of demographic and socioeconomic characteristics in treatment

Specialist explains approaches for a variety of cases encountered during procedure

The hope is that future analyses would show more patients completing the pathway and a lower rate of missed appointments.

Insights into the pathophysiology of diabetic macular edema are providing a basis for therapeutic interventions.

Multiple challenges remain for diabetic macular edema with unmet needs to improve treatment outcomes, speed of treatment benefit, and the duration of response.

Three risk-related baseline factors identified by this analysis may be associated with a potential need for injections.

Analyses of IRIS Registry data capture a snapshot of patient visits and receipt of anti-VEGF injections.

Prospective randomized trial demonstrates clinical equivalence of biosimilar and reference ranibizumab

A study including data from about 42,000 eyes found diabetic retinopathy (DR) severity is a risk factor for the progression of diabetic eye disease. Other findings support the idea that genetic factors influence the development of proliferative DR versus diabetic macular edema.

Study highlights the role of demographic and socioeconomic characteristics as contributors to disease- and treatment-related disparities among patients with diabetic macular edema.

Phase 1b data show improved vision and reduced macular edema in patients, with only 3 loading doses and minimal re-treatments.

Results support further research investigating transforming growth factor-β-Induced Gene Human Clone 30 (BIGH3).

Manufacturers are stepping up to design products that will help maximize the safety and efficiency of intravitreal injection.

The benefit is robust across a variety of demographics and baseline disease characteristics, according to data.

Study offers a real-world scenario of a very specific, but frequent and crucial aspect of the care of patients with diabetes, suggests clinician